Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 2/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.49 |
| ▸ | NAMPT | P43490 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.46 |
| ▸ | MLYCD | O95822 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3634350 | 0.81 | NAAA (0.87) | NAAASMN1; SMN2HDAC3HDAC1TSHR | |
| SCHEMBL3241002 | 0.79 | HDAC3 (0.74) | NAAASMN1; SMN2HDAC3HDAC1HDAC2 | |
| SCHEMBL29708225 | 0.79 | HDAC3 (0.74) | NAAASMN1; SMN2HDAC3HDAC1HDAC2 | |
| SCHEMBL15738287 | 0.79 | SMN1; SMN2 (0.54) | SMN1; SMN2HDAC3HDAC1TSHRHTT | |
| SCHEMBL28326194 | 0.79 | L3MBTL1 (0.73) | NAAASMN1; SMN2TSHRHTTL3MBTL1 | |
| SCHEMBL8872720 | 0.77 | KDM4E (0.57) | NAAASMN1; SMN2TSHRHTTL3MBTL1 | |
| SCHEMBL13113096 | 0.77 | HCAR2 (0.48) | NAAASMN1; SMN2HDAC3HDAC1HTT | |
| SCHEMBL20164076 | 0.76 | SMN1; SMN2 (0.69) | NAAASMN1; SMN2TSHRHTTL3MBTL1 | |
| SCHEMBL7879263 | 0.76 | EPHX2 (0.46) | SMN1; SMN2HDAC3HDAC1TSHRL3MBTL1 | |
| SCHEMBL10779959 | 0.75 | NAAA (1.00) | NAAASMN1; SMN2HDAC3HDAC1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8097708-B2 | 10a-Azalide compound | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-8097708-B2 | 10a-Azalide compound | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-20090281292-A1 | 10a-Azalide Compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2009-11-12 | — | — | US | disclosed |
| US-20090281292-A1 | 10a-Azalide Compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2009-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281292-A1 | 10a-Azalide Compound | IL17A, AZI2, HDAC9 | NAAA 822/4885SMN1; SMN2 3120/4885HDAC3 78/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.